Major Novartis Shareholder Urges Board Shake-Up After Trial Setbacks
NovartisSigSignificance3.72SenSentiment-5.01EnvEnvironment0.00SocSocial-0.37GovGovernance-4.16
Samra urged Novartis Chairman Giovanni Caforio to act, calling for board changes as drug trial setbacks raise doubts about management and deal execution. Asset manager Artisan, among Novartis’ 20 largest shareholders, joined the criticism of M&A value destruction, citing the 2024 MorphoSys acquisition. Novartis said guidance is unchanged and highlighted its pipeline and shareholder-friendly capital allocation.
Coverage (11)
- Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning (finance.yahoo.com)
- Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy (pharmexec.com)
- Novartis Investor's Share Concerns Over M&A Strategy: Report (pharmexec.com)
- Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks (finance.yahoo.com)
- Trial misses prompt shake-up call from major Novartis stockholder (thepharmaletter.com)
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flops (biospace.com)
- Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge (finance.yahoo.com)
- Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters (fiercepharma.com)
- Artisan Partners’ Director Calls for Novartis Board Shake-Up (pharmexec.com)
- EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks (reuters.com)
- Exclusive-Major Novartis shareholder calls for board shake-up after drug trial setbacks (kfgo.com)